Back to top
more

Syros Pharmaceuticals (SYRS)

(Delayed Data from NSDQ)

$5.51 USD

5.51
169,239

+0.08 (1.47%)

Updated May 15, 2024 04:00 PM ET

After-Market: $5.53 +0.02 (0.36%) 7:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Can Illumina (ILMN) Spring a Surprise this Earnings Season?

Illumina Inc. (ILMN), a leading provider of tools and integrated systems for analysis of genetic variation and function, is scheduled to report first-quarter 2017 financial results on Apr 25, after the closing bell.

    Integra LifeSciences (IART) Q1 Earnings: A Beat in Store?

    We expect Integra LifeSciences Holdings Corporation (IART) to beat expectations when it reports its first-quarter 2017 results, after market close on Apr 26.

      GNC Holdings (GNC) Q1 Earnings: Disappointment in Store?

      GNC Holdings, Inc. (GNC) -- a specialty retailer of health and nutrition related products -- is scheduled to report first-quarter 2017 financial results on Apr 18, before the opening bell.

        What's in Store for Walgreens Boots (WBA) in Q2 Earnings?

        Walgreens Boots Alliance, Inc (WBA) is slated to release second-quarter 2017 results, before the market opens on Apr 5.

          Anupama Mukhopadhyay headshot

          Can Syros Pharmaceuticals (SYRS) Run Higher on Strong Earnings Estimate Revisions?

          Syros Pharmaceuticals (SYRS) seems to be a compelling pick on the back of its solid estimate revisions both in the current year and the current quarter.

            Can The Uptrend Continue for Syros Pharmaceuticals (SYRS)?

            Investors certainly have to be happy with Syros Pharmaceuticals Inc (SYRS) and its short term performance

              Syros Pharmaceuticals Stock: 3 Reasons Why SYRS Is a Top Choice for Momentum Investors

              Let's focus on Syros Pharmaceuticals, Inc. (SYRS) as this momentum stock is looking especially impressive right now.